While some analysts questioned why Medtronic would leave a fast-growing market, others backed the company’s plan to focus on segments with higher margins.

Medical device maker Medtronic said on Wednesday it plans to separate its diabetes business, which houses its insulin pumps and other wearable devices, into a stand-alone company. The new company will be headed by Que Dallara,

Medtronic anticipates the separation of its diabetes business unit into a wholly separate entity to complete within 18 months.